Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020265

PRESIDENT AND CEO sold 12,000 shares at an average $24.92 ($299,073)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-25 Sale : show line 1 in the form 10b5-1 −3,793 $24.53 $93,042 1,071,732 I
2024-07-25 Sale : show line 2 in the form 10b5-1 −8,164 $25.10 $204,920 1,063,568 I
2024-07-25 Sale : show line 3 in the form 10b5-1 −43 $25.83 $1,111 1,063,525 I
Open-market sales · 12,000 sh · avg $24.92 · $299,073
Loading xslF345X05/form4-07292024_090754.xml…